Qingming Yu - Sinopharm Group Executive Director
| SHTDFDelisted Stock | USD 2.70 0.00 0.00% |
Director
Mr. Yu Qingming serves as Executive Director of the company. He was working in the pharmaceutical industry for 31 years, with experience in the management of pharmaceuticals, health products and medical devices and holds the professional title of senior engineer. Mr. Yu graduated from Shanghai Medical Equipment College in 1987, and graduated from the Central Party School majoring in Economic Management in 2001. From July 1987 to April 1990, Mr. Yu successively served as Secretary of Communist League Branch at Beijing Pharmaceutical Station of China National Pharmaceutical Group Co., Ltd., Secretary to the General Manager and Secretary to the Administrative Party Branch of China Medical Instrument Corporationrationration. From April 1990 to February 1997, he served in the State Pharmaceutical Administration, serving as Deputy Director, Chief Director and Department Secretary of the General Office. From February 1997 to December 2009, he successively served as Deputy General Manager of the China Sales Department and Manager of the Corporationrationrate Management Department, Assistant to Chairman, Vice President and Executive President of Zhuhai United Laboratories Co., Ltd. and Executive President of Federal Pharmaceutical International Holdings Limited. Mr. Yu was the Director, General Manager and Party Secretary of China Medical Instrument Corporation from December 2009 to August 2010. Since August 2010, Mr. Yu was in a senior management position of China National Scientific Instruments and Materials Co., Ltd. and China National Medical Device Co., Ltd. Since November 2016, he served as Chairman and Party Secretary of China National Scientific Instruments and Materials Co., Ltd. and China National Medical Device Co., Ltd. since 2018.
| Age | 59 |
| Tenure | 6 years |
| Phone | 86 21 2305 2666 |
| Web | https://www.sinopharmgroup.com.cn |
Sinopharm Group Management Efficiency
The company has return on total asset (ROA) of 0.0364 % which means that it generated a profit of $0.0364 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1319 %, meaning that it generated $0.1319 on every $100 dollars invested by stockholders. Sinopharm Group's management efficiency ratios could be used to measure how well Sinopharm Group manages its routine affairs as well as how well it operates its assets and liabilities.Sinopharm Group Co has accumulated 8.42 B in total debt with debt to equity ratio (D/E) of 0.89, which is about average as compared to similar companies. Sinopharm Group has a current ratio of 1.28, suggesting that it may have difficulties to pay its financial obligations in time and when they become due. Debt can assist Sinopharm Group until it has trouble settling it off, either with new capital or with free cash flow. So, Sinopharm Group's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sinopharm Group sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sinopharm to invest in growth at high rates of return. When we think about Sinopharm Group's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 2 records | DIRECTOR Age | ||
| Wanyong Lian | SINOPHARM GROUP LTD | 52 | |
| Yijian Wu | SINOPHARM GROUP LTD | 53 | |
Management Performance
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0364 |
Sinopharm Group Leadership Team
Elected by the shareholders, the Sinopharm Group's board of directors comprises two types of representatives: Sinopharm Group inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sinopharm. The board's role is to monitor Sinopharm Group's management team and ensure that shareholders' interests are well served. Sinopharm Group's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sinopharm Group's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yijian Wu, Non-Executive Director | ||
| Xiaojuan Li, Chief Officer | ||
| Qingming Yu, Executive Director | ||
| Yong Liu, Chief Legal Advisor and VP | ||
| Shuangjun Xu, Vice President | ||
| Xiuchang Jiang, CFO VP | ||
| Wanyong Lian, Supervisor | ||
| Maisong Cai, Vice President |
Sinopharm Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Sinopharm Group a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0364 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 16.78 B | |||
| Shares Outstanding | 1.34 B | |||
| Shares Owned By Insiders | 0.01 % | |||
| Shares Owned By Institutions | 51.07 % | |||
| Price To Earning | 5.67 X | |||
| Price To Book | 0.88 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Other Consideration for investing in Sinopharm Pink Sheet
If you are still planning to invest in Sinopharm Group check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sinopharm Group's history and understand the potential risks before investing.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |